Form 4: Tactic Pharma LLC Sells 33,334 Shares of Monopar Therapeutics (MNPR) at $35

Tactic Pharma LLC, a 10% owner of Monopar Therapeutics, disposed of 33,334 shares of common stock at a weighted average price of $35 on April 2, 2025, reducing its holdings to 822,255 shares.

Summary

• On April 2, 2025, Tactic Pharma LLC sold 33,334 shares of Monopar Therapeutics (MNPR) common stock.
• The shares were sold at a weighted average price of $35, with individual transactions ranging from $35.00 to $35.86.
• Following the transaction, Tactic Pharma LLC beneficially owns 822,255 shares of Monopar Therapeutics.
• The reporting persons include Tactic Pharma LLC and its managers: Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran.
• The managers disclaim ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. This is a standard disclosure of insider trading activity. The impact on sentiment depends on the context and reasons behind the sale, which are not provided.

Negatives

• Tactic Pharma LLC, a significant shareholder, reduced its stake in Monopar Therapeutics.

Risks

• Further sales by Tactic Pharma LLC could exert downward pressure on MNPR's stock price.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell the company's stock. This provides transparency to the market regarding insider transactions.

Stakeholder Impact

• Shareholders may react to the news of a significant shareholder selling shares.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Tactic Pharma LLC, Form 4, insider trading, share sale, beneficial ownership